Track BIVI and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Biovie Inc
680 W. Nye Lane, Carson City, NV, United States, 89703
IPO
2014
Employees
13
Industry
Biotechnology
Sector
Healthcare
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q4 20230+1
1
Q3 20232-2
0
Q2 20232-2
0
3-quarter cumulative
4 sells1 buys
Analyst Ratings
No coverage data
No analyst ratings data available